DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
التنسيق:	Journal article
اللغة:	English
منشور في:	Oxford University Press 2014

مواد مشابهة

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
حسب: Gupta, A, وآخرون
منشور في: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
حسب: Gupta, A, وآخرون
منشور في: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
حسب: Robert, C, وآخرون
منشور في: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
حسب: Robert, C, وآخرون
منشور في: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
حسب: Kirkwood, J, وآخرون
منشور في: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
حسب: Flaherty, K, وآخرون
منشور في: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
حسب: K. Haslett, وآخرون
منشور في: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
حسب: Edmund Poon, وآخرون
منشور في: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
حسب: Jessie Villanueva, وآخرون
منشور في: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
حسب: Paolo A. Ascierto, وآخرون
منشور في: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
حسب: Eva Marie Erfurth, وآخرون
منشور في: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
حسب: Andrea Gazzin, وآخرون
منشور في: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
حسب: Tahar Sif eddine Bouchema, وآخرون
منشور في: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
حسب: Pacey, S, وآخرون
منشور في: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
حسب: Anne L Estep, وآخرون
منشور في: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
حسب: Sara Bjursten, وآخرون
منشور في: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
حسب: Sarah J. Welsh, وآخرون
منشور في: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
حسب: Blessie Elizabeth Nelson, وآخرون
منشور في: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
حسب: Sarit Cohen‐Rabbie, وآخرون
منشور في: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
حسب: Hui-Ju Huang, وآخرون
منشور في: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
حسب: Leijen, S, وآخرون
منشور في: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
حسب: Leijen, S, وآخرون
منشور في: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
حسب: Bengt Tholander, وآخرون
منشور في: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
حسب: Ken Saijo, وآخرون
منشور في: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
حسب: Anaïs Roeser, وآخرون
منشور في: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
حسب: Lovisa Falkman, وآخرون
منشور في: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
حسب: Clare Judith Stones, وآخرون
منشور في: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
حسب: Jan Leipe, وآخرون
منشور في: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
حسب: Matthew R. Kroll, وآخرون
منشور في: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
حسب: Shivshankari Rajkumar, وآخرون
منشور في: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
حسب: J. Steininger, وآخرون
منشور في: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
حسب: I. V. Samoylenko, وآخرون
منشور في: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
حسب: B. Ziółkowska, وآخرون
منشور في: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
حسب: Michael J. Vido, وآخرون
منشور في: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
حسب: Zeynep Eroglu, وآخرون
منشور في: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
حسب: Raphael Reinhard, MD, وآخرون
منشور في: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
حسب: Manrose Singh, وآخرون
منشور في: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
حسب: Sivakamavalli Jeyachandran
منشور في: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
حسب: Ariane Fizazi, وآخرون
منشور في: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
حسب: Marit A. C. Vermunt, وآخرون
منشور في: (2021-08-01)